PF-07209326 for Sickle Cell Anemia

"The safety of PF-07209326 is assessed as a 1, since this Phase 1 trial has limited data supporting its efficacy and security."

"The requirements for entrance into this clinical trial specify that the age of participants must fall between 18 and 55 years old."

"The University of Illinois at Chicago Clinical Research Center in New york, Columbia University Medical Center - Herbert Irving Pavilion in Atlanta, and Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Centre in Washington are among the 12 recruiting sites for this clinical trial. Several additional medical centres are also participating."

"In order to be considered for this clinical trial, applicants must display anemic tendencies, a diagnosis of sickle cell disease and age between 18-55. The total number of participants being sought is 54 individuals."

"Indeed, the trial is actively recruiting. It was first advertised on February 5th 2020 with its most recent update done on October 10th 2022. 54 participants are required to be enrolled over a span of 12 medical centres."

"This clinical trial, lasting from Day 1 to 85 (SAD) or 113 (MD), strives to evaluate the frequency, severity, and root cause of adverse events correlated with treatment. Secondary goals include measuring MD AUCtau (Area under the curve over dosing interval tau for one week after starting and ending doses), SAD Dose Normalized Cmax, and SAD Dose Normalised AUCinf."

"To make this clinical trial a success, 54 persons that meet the stipulated requirements need to take part. These individuals can join from multiple sites such as University of Illinois at Chicago Clinical Research Center in New york City and Columbia University Medical Centre - Herbert Irving Pavilion located in Atlanta, Georgia."